Frailty Markers Affect Outcomes Among Patients Receiving CAR T-Cell Therapy
Recent research highlights the importance of considering frailty markers—particularly physical deconditioning and malnutrition—in patients with lymphoma receiving chimeric antigen receptor T-cell (CAR-T) therapy.
“Patients undergoing...
“Hospital at Home” Program Is Safe and Useful in Hematologic Malignancies
At the American Society of Hematology meeting, presenters shared a novel “hospital at home” (HaH) program that provided inpatient-level care at home for patients...
New Efficacy and Safety Data on BTK Degrader BGB-16673
New data show that the Bruton’s tyrosine kinase (BTK) degrader BGB-16673 produces robust and deepening responses and has a tolerable safety profile in patients...
Second-Generation CAR T-Cell Therapy Effective in Relapsed/Refractory MCL
A new study has found that GLPG5101 led to deep and durable responses in patients with high-risk, aggressive, relapsed or refractory mantle cell lymphoma...